SUMMARY
At the EHA annual meeting of 2019, interesting new data with regard to myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN) were presented. For patients with high-risk myelofibrosis (MF) who have failed or are intolerant to ruxolitinib (rux) as well as for patients with higher risk MDS, the prognosis is poor and treatment options are few. There is still a large unmet medical need for these patient groups and new therapies are eagerly awaited. The same holds true for patients with advanced systemic mastocytosis (AdvSM). For this patient group very promising data about a new inhibitor of KIT D816V were presented. In contrast, most chronic myeloid leukemia (CML) patients have a much brighter outlook with the currently available tyrosine kinase inhibitors (TKI) treatments and some can even stop their TKI and have a durable treatment-free remission (TFR). A short update of the DASFREE and ENESTfreedom data will be discussed below. Some CML patients however do not reach their treatment goals and are waiting for new treatment options. Also data on pregnancy outcomes in CML patients were discussed.
(BELG J HEMATOL 2019;10(5):188–94)
